Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth
Circulation · 28.05.2024 · 149 (22) · 1729-1748
DOI: 10.1161/circulationaha.123.066911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 28.05.2024. Verfasst von Tal Caller und 15 weiteren Autor:innen. Beteiligte Einrichtung: Neufeld and Tamman Cardiovascular Research Institutes, School of Medicine, Tel Aviv University, Israel (T.C., I.R., O.S.-T., D.L., Y.S., R.S., M.N., …. Hauptthemen laut MEDLINE: Extracellular Vesicles, Heart Failure, Myocardial Infarction. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Myocardial infarction (MI) and heart failure are associated with an increased incidence of cancer. However, the mechanism is complex and unclear. Here, we aimed to test our hypothesis that cardiac small extracellular vesicles (sEVs), particularly cardiac mesenchymal stromal cell–derived sEVs (cMSC-sEVs), contribute to the link between post-MI left ventricular dysfunction (LVD) and cancer. METHODS: We purified and characterized sEVs from post-MI hearts and cultured cMSCs. Then, we analyzed cMSC-EV cargo and proneoplastic effects on several lines of cancer cells, macrophages, and endothelial cells. Next, we modeled heterotopic and orthotopic lung and breast cancer tumors in mice with post-MI LVD. We transferred cMSC-sEVs to assess sEV biodistribution and its effect on tumor growth. Finally, we tested the effects of sEV depletion and spironolactone treatment on cMSC-EV release and tumor growth. RESULTS: Post-MI hearts, particularly cMSCs, produced more sEVs with proneoplastic cargo than nonfailing hearts did. Proteomic analysis revealed unique protein profiles and higher quantities of tumor-promoting cytokines, proteins, and microRNAs in cMSC-sEVs from post-MI hearts. The proneoplastic effects of cMSC-sEVs varied with different types of cancer, with lung and colon cancers being more affected than melanoma and breast cancer cell lines. Post-MI cMSC-sEVs also activated resting macrophages into proangiogenic and protumorigenic states in vitro. At 28-day follow-up, mice with post-MI LVD developed larger heterotopic and orthotopic lung tumors than did sham-MI mice. Adoptive transfer of cMSC-sEVs from post-MI hearts accelerated the growth of heterotopic and orthotopic lung tumors, and biodistribution analysis revealed accumulating cMSC-sEVs in tumor cells along with accelerated tumor cell proliferation. sEV depletion reduced the tumor-promoting effects of MI, and adoptive transfer of cMSC-sEVs from post-MI hearts partially restored these effects. Finally, spironolactone treatment reduced the number of cMSC-sEVs and suppressed tumor growth during post-MI LVD. CONCLUSIONS: Cardiac sEVs, specifically cMSC-sEVs from post-MI hearts, carry multiple protumorigenic factors. Uptake of cMSC-sEVs by cancer cells accelerates tumor growth. Treatment with spironolactone significantly reduces accelerated tumor growth after MI. Our results provide new insight into the mechanism connecting post-MI LVD to cancer and propose a translational option to mitigate this deadly association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neufeld and Tamman Cardiovascular Research Institutes, School of Medicine, Tel Aviv University, Israel (T.C., I.R., O.S.-T., D.L., Y.S., R.S., M.N., N.N.-S., J.L.).
- Lev Leviev Cardiovascular and Thoracic Center (T.C., I.R., O.S.-T., D.L., Y.S., N.N.-S., J.L.), Sheba Medical Center, Tel Hashomer, Israel.
- Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital, Cancer Research Center (R.S.), Sheba Medical Center, Tel Hashomer, Israel.
- Cancer Research Center and Wohl Centre for Translational Medicine (E.G.-S., D.D.), Sheba Medical Center, Tel Hashomer, Israel.
- Faculty of Engineering, Bar-Ilan University, Ramat Gan, Israel (M.M., I.K., R.P.).
- Department of Biological Sciences, University of Notre Dame, IN (A.B., C.D'S.-S.).
ORCID-Profile: Tal Caller, Itai Rotem, Ruty Shai, Alex Boomgarden, Nili Naftali-Shani, Jonathan Leor
Förderung
- NIGMS NIH HHS
Zitieren
APA
Caller, T., Rotem, I., Shaihov-Teper, O., Lendengolts, D., Schary, Y., Shai, R., Glick-Saar, E., Dominissini, D., Motiei, M., Katzir, I., Popovtzer, R., Nahmoud, M., Boomgarden, A., D'Souza-Schorey, C., Naftali-Shani, N., & Leor, J. (2024). Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth. Circulation, 149(22), 1729-1748. https://doi.org/10.1161/circulationaha.123.066911
Vancouver
Caller T, Rotem I, Shaihov-Teper O, Lendengolts D, Schary Y, Shai R, et al. Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth. Circulation. 2024;149(22):1729-1748. doi:10.1161/circulationaha.123.066911
BibTeX
@article{Caller2024,
author = {Caller, Tal and Rotem, Itai and Shaihov-Teper, Olga and Lendengolts, Daria and Schary, Yeshai and Shai, Ruty and Glick-Saar, Efrat and Dominissini, Dan and Motiei, Menachem and Katzir, Idan and Popovtzer, Rachela and Nahmoud, Merav and Boomgarden, Alex and D'Souza-Schorey, Crislyn and Naftali-Shani, Nili and Leor, Jonathan},
title = {Small Extracellular Vesicles From Infarcted and Failing Heart Accelerate Tumor Growth},
journal = {Circulation},
year = {2024},
volume = {149},
number = {22},
pages = {1729--1748},
doi = {10.1161/circulationaha.123.066911}
}
EUVIMED